UY32238A - Agonistas de los receptores de la melanocortina - Google Patents

Agonistas de los receptores de la melanocortina

Info

Publication number
UY32238A
UY32238A UY0001032238A UY32238A UY32238A UY 32238 A UY32238 A UY 32238A UY 0001032238 A UY0001032238 A UY 0001032238A UY 32238 A UY32238 A UY 32238A UY 32238 A UY32238 A UY 32238A
Authority
UY
Uruguay
Prior art keywords
agelists
respect
melanocortine
receptors
melanocortin receptor
Prior art date
Application number
UY0001032238A
Other languages
English (en)
Inventor
Lee Koo
Lee Sang Dae
Moon Sang Pil
Ahn In Ae
choi sung Pil
Lee Hyun Ho
Shim Dong Sup
Lee Hyun Min
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of UY32238A publication Critical patent/UY32238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente inveción se refiere a un compuesto que tiene una buena actividad agonista con respecto al receptor de la melanocortina, o una sal farmacéuticamente aceptable o un isómero del mismo, y a una composición agonista con respecto al receptor de la melanocortina que comprende el mismo como un ingrediente activo.
UY0001032238A 2008-11-12 2009-11-11 Agonistas de los receptores de la melanocortina UY32238A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12

Publications (1)

Publication Number Publication Date
UY32238A true UY32238A (es) 2010-01-05

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032238A UY32238A (es) 2008-11-12 2009-11-11 Agonistas de los receptores de la melanocortina

Country Status (26)

Country Link
US (4) US8039622B2 (es)
EP (1) EP2350060B1 (es)
JP (1) JP5399506B2 (es)
KR (1) KR101141976B1 (es)
CN (1) CN102282141B (es)
AR (1) AR074109A1 (es)
AU (1) AU2009314827B2 (es)
BR (1) BRPI0921063B8 (es)
CA (1) CA2742248C (es)
CL (1) CL2011001073A1 (es)
CO (1) CO6362006A2 (es)
CR (1) CR20110250A (es)
EA (1) EA019146B1 (es)
EC (1) ECSP11011026A (es)
GE (1) GEP20135850B (es)
IL (1) IL212468A0 (es)
MA (1) MA32774B1 (es)
MX (1) MX2011004583A (es)
NZ (1) NZ592512A (es)
PE (1) PE20110684A1 (es)
TN (1) TN2011000222A1 (es)
TW (1) TWI389903B (es)
UA (1) UA99555C2 (es)
UY (1) UY32238A (es)
WO (1) WO2010056022A2 (es)
ZA (1) ZA201103154B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
RS62701B1 (sr) 2011-12-29 2022-01-31 Rhythm Pharmaceuticals Inc Postupak lečenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
MX2014011419A (es) 2012-04-25 2014-11-25 Hoffmann La Roche Clorhidrato de (3,4-dicloro-fenil)-((s)-3-propil-pirrolidin-3-il)- metanona y procesos de manufacturacion.
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
JP7051106B2 (ja) 2015-09-30 2022-04-11 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
DK3953327T3 (da) * 2019-11-07 2024-02-05 Lg Chemical Ltd Melanocortin-4-receptor-agonister
IL302427A (en) 2020-10-29 2023-06-01 Lg Chemical Ltd A crystalline structure of a melanocortin receptor agonist and a method for its preparation
AU2021370072B2 (en) * 2020-10-29 2024-02-08 Lg Chem, Ltd. Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
IL302429A (en) 2020-10-29 2023-06-01 Lg Chemical Ltd A crystalline structure of a melanocortin receptor agonist and a method for its preparation
PE20231379A1 (es) 2020-10-29 2023-09-07 Lg Chemical Ltd Agonista de receptor de melanocortina-4 amorfo
JP2023548163A (ja) 2020-10-29 2023-11-15 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
US20240051944A1 (en) 2020-12-22 2024-02-15 Lg Chem, Ltd. Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor
TWI810757B (zh) * 2020-12-22 2023-08-01 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物的晶型ｉ及其製備方法
JP2024500906A (ja) 2020-12-22 2024-01-10 エルジー・ケム・リミテッド 無定形のメラノコルチン受容体アゴニストおよびその製造方法
US20240051919A1 (en) 2020-12-22 2024-02-15 Lg Chem, Ltd. Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
CN116761611A (zh) * 2021-01-21 2023-09-15 株式会社Lg化学 黑皮质素-4受体激动剂的用途
WO2022182194A1 (ko) 2021-02-26 2022-09-01 주식회사 엘지화학 멜라노코르틴-4 수용체 작용제
AU2022271119A1 (en) * 2021-05-06 2023-11-02 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
US20240239783A1 (en) 2021-05-06 2024-07-18 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
CN117255788A (zh) 2021-05-07 2023-12-19 株式会社Lg化学 黑皮质素受体激动剂化合物的有机酸盐的晶型iv及其制备方法
BR112023022334A2 (pt) 2021-05-07 2023-12-26 Lg Chemical Ltd Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
AU2001249296B2 (en) 2000-03-23 2005-03-24 Merck Sharp & Dohme Corp. Substituted piperidines as melanocortin receptor agonists
CA2403631A1 (en) 2000-03-23 2001-09-27 Brenda L. Palucki Spiropiperidine derivatives as melanocortin receptor agonists
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
JP2004506687A (ja) 2000-08-23 2004-03-04 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン受容体作働薬としての置換ピペリジン類
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
CA2433025A1 (en) 2001-01-23 2002-08-01 Chaoyu Xie Substituted piperidines/piperazines as melanocortin receptor agonists
CA2439119A1 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE341327T1 (de) 2001-02-28 2006-10-15 Merck & Co Inc Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
HUP0303376A3 (en) 2001-02-28 2007-08-28 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
AR043434A1 (es) 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1685102A4 (en) * 2003-11-12 2008-08-20 Lg Life Sciences Ltd melanocortin
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
CA2573714A1 (en) 2004-07-16 2006-02-23 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE602005018779D1 (de) 2004-07-19 2010-02-25 Merck & Co Inc Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1928460A2 (en) 2005-08-01 2008-06-11 Pfizer Limited Mc4r-agonists for the treatment of urinary tract dysfunction
US20080269233A1 (en) 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AU2006297452A1 (en) 2005-09-30 2007-04-12 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
DK1989196T3 (da) 2006-02-23 2013-04-15 Pfizer Ltd Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
DK2348016T3 (en) 2006-06-09 2016-05-30 Synact Pharma Aps Phenylpyrrolaminoguanidine derivatives
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
JP2010512304A (ja) 2006-09-27 2010-04-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレータとしてのアシル化ピペリジン誘導体
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
US8183243B2 (en) 2012-05-22
US20110245500A1 (en) 2011-10-06
GEP20135850B (en) 2013-06-10
TW201022246A (en) 2010-06-16
CN102282141A (zh) 2011-12-14
AU2009314827B2 (en) 2012-04-05
EA019146B1 (ru) 2014-01-30
MX2011004583A (es) 2011-06-01
KR20100053458A (ko) 2010-05-20
JP2012508730A (ja) 2012-04-12
EA201170676A1 (ru) 2011-12-30
TN2011000222A1 (en) 2012-12-17
US20110224219A1 (en) 2011-09-15
ZA201103154B (en) 2012-01-25
US8039622B2 (en) 2011-10-18
CO6362006A2 (es) 2012-01-20
AR074109A1 (es) 2010-12-22
PE20110684A1 (es) 2011-09-28
US8288386B2 (en) 2012-10-16
UA99555C2 (en) 2012-08-27
ECSP11011026A (es) 2011-06-30
NZ592512A (en) 2012-12-21
BRPI0921063B8 (pt) 2021-05-25
AU2009314827A1 (en) 2010-05-20
CN102282141B (zh) 2014-09-10
WO2010056022A3 (en) 2010-09-10
US8236955B2 (en) 2012-08-07
CR20110250A (es) 2011-08-26
WO2010056022A2 (en) 2010-05-20
US20100120783A1 (en) 2010-05-13
CA2742248C (en) 2014-01-14
BRPI0921063B1 (pt) 2021-03-16
CL2011001073A1 (es) 2011-10-07
TWI389903B (zh) 2013-03-21
CA2742248A1 (en) 2010-05-20
EP2350060B1 (en) 2013-09-18
KR101141976B1 (ko) 2012-05-07
JP5399506B2 (ja) 2014-01-29
MA32774B1 (fr) 2011-11-01
IL212468A0 (en) 2011-06-30
EP2350060A2 (en) 2011-08-03
EP2350060A4 (en) 2012-07-25
BRPI0921063A2 (pt) 2015-08-25
US20110237795A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
UY32238A (es) Agonistas de los receptores de la melanocortina
DOP2011000104A (es) Combinacion de una insulina y un agonista de glp-1
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
CL2012000887A1 (es) Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
IN2012DN01241A (es)
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
UY32223A (es) Nuevos compuestos sustituidos con halogenos
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
ATE509636T1 (de) Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2013000732A1 (es) Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
EA201001230A1 (ru) Пестицидные смеси
UY32440A (es) Mezclas de plaguicidas
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
EA201001234A1 (ru) Пестицидные смеси
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.
CO6420321A2 (es) Un derivado de cianopirimidina novedoso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190902